The biotech sector continues to offer significant growth opportunities for investors seeking companies with breakthrough therapies and strong commercial potential. BTIG Research recently released their Biotech Best Ideas Call, highlighting two standout companies they believe are positioned for substantial upside in the coming year.
The research firm’s analysis focuses on companies with innovative treatments addressing significant unmet medical needs, particularly in oncology. Their top selections feature companies with recently approved therapies that are already demonstrating commercial success.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) BTIG’s top pick in the biotech space is Syndax Pharmaceuticals, which they’ve assigned a price target of $56, representing approximately 260% upside potential from current levels.
The company, with a $1.3 billion market cap, has secured a first-mover advantage with Revuforj (revumenib), the first and only approved menin inhibitor. The drug is already showing strong launch momentum in KMT2Ar Acute Leukemia.
BTIG highlights near-term label expansion opportunities into nNPM1 AML and multiple ongoing frontline/combination studies that could unlock a market opportunity exceeding $5 billion.
Additionally, Syndax offers a dual franchise with Niktimvo (axatilimab), which is already exceeding expectations. Combined with a strong cash position, BTIG believes Syndax is positioned to deliver durable revenue growth.
Verastem Inc (NASDAQ:VSTM) BTIG’s second recommendation is Verastem Oncology, with a $20 price target representing approximately 106% upside potential.
With a market cap of $0.6 billion, Verastem received approval in May 2025 for AVMAPKI FAKZYNJA (avutometinib and defactinib), the first targeted therapy for KRAS-mutant recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
The company has demonstrated strong early commercial traction, generating $2.1 million in the first six weeks following approval, with rapid payer coverage and broad physician adoption. BTIG notes additional pipeline expansion opportunities, including promising signals in pancreatic cancer with the RAMP 205 expansion cohort nearing completion of enrollment.
The firm also highlights Verastem’s differentiated KRAS G12D inhibitor as providing additional upside potential that is not currently reflected in the company’s valuation.
Both companies face potential risks, including clinical trial outcomes and competitive pressures that could impact their market positions.
For Syndax, worse-than-expected efficacy or safety signals in ongoing clinical trials could significantly impact valuation, while Verastem faces risks related to its confirmatory RAMP301 trial and commercial execution in niche oncology markets.
source :
